Skip to content
value.today

Accolade, Inc.

ACCDUnlisted company
$860 Mlast known market cap, Jan 2024 — no current value
Compare
World rank
—
no current market cap
Revenue
$414 M
For year ending February-2024
Net income
$-100 M
-24.1% margin
SEC filing
Employees
2,370
As on Feb-2023
value.today research

Accolade, Inc. in brief

Accolade, Inc. is an unlisted company in the Healthcare Information Services industry, based in California, USA. It was founded in 2007. In the year to February 2024 it had sales of $414 M and a net loss of $100 M. It employs about 2,370 people.

Written from the figures on this page, so it changes when they do. The date of each figure is under How current the figures are.

About Accolade, Inc.

Accolade is a Compassionate Advisers, Clinical Expertise and Intelligent Technology company. The headquarters is in USA.

Accolade Annual Total Revenue for year ending Feb-2023 was 363 million USD and and Net loss for year ending Feb-2023 was -459 million USD.

Accolade Annual Total Revenue for year ending Feb-2022 was 310 million USD and and Net loss for year ending Feb-2022 was -123 million USD.

Read more

As on Feb-2023, Accolade has 2,370 employees.

Accolade, Inc. timeline

7 events, 2007–2023
  1. 2007
  2. 🏁
    · approximate
    Founded
  3. 2010
  4. ✎
    Renamed Accolade, Inc.
    Formerly Accolade LLC.
  5. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  6. 2020
  7. 📈
    Listed on New York Stock Exchange as ACCD
  8. 🔔
    Initial public offering on Nasdaq
    Final prospectus filed with the SEC on 2 July 2020; shares registered for exchange trading on 25 June 2020.
  9. 2021
  10. •
    Legal Entity Identifier issued
    LEI 549300PHKG8J7A22NF08 registered.
  11. 2023
  12. 💰
    Record revenue of $414 million
    FY2023, the highest of the 6 years on record.

Events of Accolade, Inc. from Wikidata, SEC EDGAR, the GLEIF LEI register and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

More about Accolade, Inc.

Acquisitions and changes
Taken over: the company reported a change in control and the delisting of its shares to the SEC on 8 April 2025 (Form 8-K).

Market cap history

$0 M$646 M$1.3 B$1.9 B$2.6 B2021202220232024

World rank over time

▼ down 4,449 places since 2021
2021-01-01: #4932#4,93220212022-01-07: #7714#7,71420222022-12-25: #11252#11,25220222023-07-30: #8288#8,28820232024-01-05: #9381#9,3812024

Rank in USA: #1,534 (Jan 2021) · #2,247 (Jan 2022) · #2,440 (Dec 2022) · #2,050 (Jul 2023) · #2,138 (Jan 2024)

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
—
Price / book
—
Free cash flow yield
—
Net margin
-24.1%
Operating margin
-27.6%
Return on equity
-22.4%
Liabilities / assets
43.5%
Net debt
$-12M
Revenue growth
+14.1%
Revenue per employee
$175 K
Profit per employee
$-42 K

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Feb 2019: revenue $95M, net income $-57M$95MFY19Fiscal year ending Feb 2020: revenue $133M, net income $-51M$133MFY20Fiscal year ending Feb 2021: revenue $170M, net income $-51M$170MFY21Fiscal year ending Feb 2022: revenue $310M, net income $-123M$310MFY22Fiscal year ending Feb 2023: revenue $363M, net income $-460M$363MFY23Fiscal year ending Feb 2024: revenue $414M, net income $-100M$414MFY24
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Feb 2024$414M+14.1%$-114M$-100M-24.1%
Feb 2023$363M+17.1%$-464M$-460M-126.6%
Feb 2022$310M+82.0%$-126M$-123M-39.7%
Feb 2021$170M+28.6%$-47M$-51M-29.7%
Feb 2020$133M+39.8%$-48M$-51M-38.8%
Feb 2019$95M—$-54M$-57M-59.6%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Feb 2024$-16M$5M$-21M$-1.33—
Feb 2023$-41M$2M$-43M$-6.45—
Feb 2022$-62M$3M$-65M$-1.93—
Feb 2021$-25M$2M$-27M$-1.72$0.00
Feb 2020$-34M$3M$-38M$-9.13—
Feb 2019$-17M$1M$-18M$-12.17—

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Feb 2023 (from the annual report): revenue $99M, net income $-30M$99MFeb ’23Three months to May 2023: revenue $93M, net income $-38M$93MMay ’23Three months to Aug 2023: revenue $97M, net income $-33M$97MAug ’23Three months to Nov 2023: revenue $99M, net income $-21M$99MNov ’23Three months to Feb 2024 (from the annual report): revenue $125M, net income $-8M$125MFeb ’24Three months to May 2024: revenue $110M, net income $-28M$110MMay ’24Three months to Aug 2024: revenue $106M, net income $-24M$106MAug ’24Three months to Nov 2024: revenue $105M, net income $-121M$105MNov ’24

Latest quarter to Nov 2024: revenue $105M (+5.7% on a year earlier), net income $-121M. Lighter bars: fourth quarters worked out from the annual report.

SEC filings

Official filings of Accolade, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
$414 M
Operating income
$-114 M
Net income
$-100 M

For year ending February-2024 · source: SEC filing

Balance sheet

Total assets
$788 M
Total liabilities
$343 M
Total equity
$445 M

As of February-2024

Insider trading at Accolade, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$0
open market only
Insiders on file
20
since
-$1.9 M$0Nov 2023: bought $0 (0 trades), sold $18 K (8 trades)Nov 23Dec 2023: bought $0 (0 trades), sold $29 K (9 trades)Jan 2024: bought $0 (0 trades), sold $1.9 M (12 trades)Feb 2024: bought $0 (0 trades), sold $41 K (9 trades)FebMar 2024: bought $0 (0 trades), sold $26 K (8 trades)Apr 2024: bought $0 (0 trades), sold $26 K (8 trades)May 2024: bought $0 (0 trades), sold $19 K (8 trades)MayJun 2024: bought $0 (0 trades), sold $267 K (11 trades)Jul 2024: bought $0 (0 trades), sold $18 K (11 trades)Aug 2024: bought $0 (0 trades), sold $18 K (11 trades)AugSep 2024: bought $0 (0 trades), sold $21 K (11 trades)Oct 2024: bought $0 (0 trades), sold $19 K (11 trades)Nov 2024: bought $0 (0 trades), sold $16 K (11 trades)NovDec 2024: bought $0 (0 trades), sold $116 K (11 trades)Jan 2025: bought $0 (0 trades), sold $23 K (11 trades)Feb 2025: bought $0 (0 trades), sold $29 K (10 trades)FebMar 2025: bought $0 (0 trades), sold $29 K (10 trades)Apr 2025: bought $0 (0 trades), sold $16 K (4 trades)
Bought (open market)Sold (open market)Hover a month for the totals
Accolade, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Cindy KentDirectorDisposal to the company-10,602$7.030$75 K0Form 4
filed Robert N. CavanaughPresidentDisposal to the company-222,216$7.030$1.6 M0Form 4
filed Jeffrey S. BrodskyDirectorDisposal to the company-46,810$7.030$329 K0Form 4
filed Michael W. HiltonDirectorDisposal to the company-150,946$7.030$1.1 M0Form 4
filed Peter S. KleinDirectorDisposal to the company-28,329$7.030$199 K0Form 4
filed Stephen H. BarnesChief Financial OfficerDisposal to the company-306,874$7.030$2.2 M0Form 4
filed Richard EskewEVP General CounselDisposal to the company-66,191$7.030$465 K0Form 4
filed Patricia L. WadorsDirectorDisposal to the company-27,759$7.030$195 K0Form 4

Accolade, Inc. scorecard#

Passes 5 of the 14 checks that could be worked out: strongest in growth (4 of 6), weakest in profitability (0 of 5). Fiscal year 2023.

  • Valuationnot known
  • Growth4 of 6
  • Profitability0 of 5
  • Financial health1 of 2
  • Shareholder returns0 of 1

Worked out from the statements as filed (sec), the medians of Healthcare Information Services, the 10-year Treasury yield of Nov 20, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Accolade, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Accolade, Inc.: statements by fiscal year
PeriodTrendFY 2023to Feb 29, 2024FY 2022to Feb 28, 2023FY 2021to Feb 28, 2022FY 2020to Feb 28, 2021FY 2019to Feb 29, 2020FY 2018to Feb 28, 2019
Income statement
Revenue41436331017013395
Selling and marketing1009987343023
General and administrative628199322620
Operating expenses30762826712310788
Operating income−114−464−126−47−48−54
Other non-operating income (expense)9.9−0.0−0.1−0.1−0.1−0.1
Income before tax−99−463−129−51−51−56
Income tax1.2−3.6−5.60.00.10.1
Net income including minority interests—−460−123−51−51−56
Net income attributable to shareholders−100−460−123−51−51−56
Earnings per share, basic-1.33-6.45-1.93-1.72-9.13-12.17
Earnings per share, diluted-1.33-6.45-1.93-1.72-9.13-12.17
Shares, weighted average (basic)757164295.6—
Shares, weighted average (diluted)757164295.64.6
Dividends per share———0.00——
Balance sheet
Cash and cash equivalents1863213664343343
Receivables2223219.10.3—
Other current assets16149.56.013—
Current assets28536640945449—
Property, plant and equipment1915129.214—
Right-of-use (leased) assets283033———
Goodwill2782785784.04.0—
Other intangible assets1652032450.62.1—
Total assets7889031,28647673—
Accounts payable14107.87.45.3—
Current liabilities1081191127970—
Lease liabilities (non-current)262732———
Total liabilities3434294308597—
Retained earnings−1,054−954−495−372−321—
Shareholders' equity445474856391−257−231
Total liabilities and equity7889031,28647673—
Shares outstanding787367566.0—
Cash-flow statement
Depreciation and amortization4546438.28.59.4
Share-based compensation6173739.66.05.7
Cash from operating activities−16−41−62−25−34−17
Capital expenditure−4.9−2.1−2.5−2.0−3.3−1.2
Acquisitions, net of cash acquired00−260—−0.2—
Cash from investing activities−64−7.2−264−2.4−3.5−3.1
Debt issued00288511.73.0
Debt repaid———−73—−5.0
Shares issued———439——
Cash from financing activities−563.22584282849
Change in cash−135−45−68401−9.529
Report10-K10-K10-K10-K10-K10-K

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

As of Nov 30, 2024

Events at Accolade, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.

Taken over and delisted 1 · Change in control 1 · Acquisition or sale completed 1 · Directors and officers 2 · Material agreement 3 · Shareholder rights changed 1 · Bylaws or fiscal year changed 1 · Shareholder vote 4 · Results announced 14

Accolade, Inc.: events reported to the SEC
FiledWhat happenedFiling
Taken over and delistedChange in controlAcquisition or sale completedDirectors and officersMaterial agreementShareholder rights changedBylaws or fiscal year changed8-K
Shareholder vote8-K
Material agreementResults announced8-K
Results announced8-K
Shareholder vote8-K
Results announced8-K
Results announced8-K
Results announced8-K
Results announced8-K
Shareholder vote8-K
Results announced8-K
Results announced8-K
Directors and officers8-K
Results announced8-K
Results announced8-K
Shareholder vote8-K
Material agreement8-K
Results announced8-K
Results announced8-K
Results announced8-K
Results announced8-K

As of Apr 8, 2025

Acquisitions and funding#

3 acquisitions, $841 M paid where reported · 6 private funding rounds before listing

Businesses it acquired

Acquisitions by Accolade, Inc.
AcquiredAcquisition dateCompletionPriceStakeSource
Acquisition of 2nd.MD2021—$420 M—Annual report
PlushCare2021—$414 M—Annual report
MD Insider Inc2019—$6 M—Annual report

Private share sales · funding history

Private share sales of Accolade, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Sep 2021$11 MIssued in a merger or acquisition$10 to $50 million1equitySEC
Jun 2021$325 MIssued in a merger or acquisition$250 million to $1 billion79equitySEC
Mar 2021$130 MIssued in a merger or acquisition$50 to $250 million43equitySEC
Oct 2019$20 MNo. 6$10 to $50 million1equity, optionsSEC
Mar 2018$27 MNo. 5$10 to $50 million17equity, optionsSEC
Jul 2016$55 MNo. 4$50 to $250 million4equity, optionsSEC
Jul 2015$39 MNo. 3$10 to $50 million5equitySEC
Apr 2014$3 MIssued in a merger or acquisition$2 to $10 million1equitySEC
Dec 2013$30 MNo. 2$10 to $50 million17equitySEC
Jun 2010$17 MNo. 1$10 to $50 million17equitySEC

H-1B hiring at Accolade, Inc.#

10 labor condition applications certified in fiscal 2025 for 10 positions, at a median wage of $118 K a year.

Certified, FY2025
10
#882 among companies on value.today
Worker positions
10
Median wage offered
$118 K
a year, full-time
Applications filed
10
Accolade, Inc.: most frequent H-1B job titles in fiscal 2025
Job titlePositionsMedian wage offered
SR. SOFTWARE ENGINEERSoftware Developers3$124 K
SR. BUSINESS INTELLIGENCE DEVELOPERSoftware Developers2$109 K
SR. PRODUCT ANALYSTOperations Research Analysts2$103 K
PRINCIPAL SOFTWARE ENGINEER ISoftware Developers1$146 K
SOFTWARE ENGINEER ISoftware Developers1$111 K
SOFTWARE ENGINEER IISoftware Developers1$118 K

Where: Seattle, WA 5 · Georgetown, TX 2 · Plymouth Meeting, PA 2 · Argyle, TX 1

Accolade, Inc.: labor condition applications by fiscal year
Fiscal yearCertifiedPositionsMedian wageFiled
FY20251010$118 K10
FY20241212$122 K13
FY20231010$129 K10
FY20221919$161 K19
FY20211010$106 K10
FY202055$99 K5

How Accolade, Inc. compares in Healthcare Information Services

  • Revenue$414 M · higher than 61% of 71
  • Net margin-24.1% · higher than 24% of 69
  • Revenue growth14.1% · higher than 67% of 40

Peer comparison · Healthcare Information Services

CompanyMarket capP/ENet marginRev. growth
Accolade, Inc.🇺🇸$860 M—-24.1%+14.1%
Veeva Systems Inc.🇺🇸$50.2 B49.5×29.4%+16.3%
Pro Medicus Limited🇦🇺$14.4 B81.3×——
10x Genomics, Inc.🇺🇸$9.4 B—-10.8%+5.3%
HealthEquity, Inc.🇺🇸$8.3 B35.3×17.4%+9.5%
M3, Inc.🇯🇵$7.1 B21.5×14.0%—
Doximity, Inc.🇺🇸$5.5 B39.5×21.1%+13.1%
Privia Health Group, Inc.🇺🇸$2.8 B80.9×1.4%+22.3%
Winning Health Technology Group Co., Ltd.🇨🇳$2.3 B41.3×13.8%—

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

How current the figures are

Market cap:
Jan 5, 2024 (last known)
Annual results:
For year ending February-2024
Balance sheet:
As of February-2024
Employees:
As on Feb-2023
Profile updated:
Nov 14, 2026

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Accolade, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Accolade, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Accolade, Inc.? Suggest a correction